TIMENTIN
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Apr 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TIMENTIN is an injectable small-molecule antibiotic combination approved in 1985 for bacterial infections. The drug is administered via injection and treats serious infections across multiple indications. As a legacy injectable antibiotic, it remains a standard-of-care option in hospital and acute-care settings.
LOE Approaching
Product faces imminent loss of exclusivity with moderate competitive pressure (30), indicating a contracting team and focus on transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TIMENTIN offers limited career growth due to its LOE-approaching status and lack of active linked job openings. Career roles on this product focus on managed transition, supply-chain optimization, and cost management rather than product innovation or expansion.
Account ManagerSupply Chain Specialist
Worked on TIMENTIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.